JP2022511453A5 - - Google Patents

Info

Publication number
JP2022511453A5
JP2022511453A5 JP2021530800A JP2021530800A JP2022511453A5 JP 2022511453 A5 JP2022511453 A5 JP 2022511453A5 JP 2021530800 A JP2021530800 A JP 2021530800A JP 2021530800 A JP2021530800 A JP 2021530800A JP 2022511453 A5 JP2022511453 A5 JP 2022511453A5
Authority
JP
Japan
Prior art keywords
nucleic acid
isolated nucleic
injection
vector
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021530800A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511453A (ja
JP7616995B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063289 external-priority patent/WO2020112802A1/en
Publication of JP2022511453A publication Critical patent/JP2022511453A/ja
Publication of JP2022511453A5 publication Critical patent/JP2022511453A5/ja
Priority to JP2024128634A priority Critical patent/JP2024177670A/ja
Application granted granted Critical
Publication of JP7616995B2 publication Critical patent/JP7616995B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021530800A 2018-11-28 2019-11-26 神経変性疾患のための遺伝子治療 Active JP7616995B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024128634A JP2024177670A (ja) 2018-11-28 2024-08-05 神経変性疾患のための遺伝子治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862772230P 2018-11-28 2018-11-28
US62/772,230 2018-11-28
PCT/US2019/063289 WO2020112802A1 (en) 2018-11-28 2019-11-26 Gene therapies for neurodegenerative disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024128634A Division JP2024177670A (ja) 2018-11-28 2024-08-05 神経変性疾患のための遺伝子治療

Publications (3)

Publication Number Publication Date
JP2022511453A JP2022511453A (ja) 2022-01-31
JP2022511453A5 true JP2022511453A5 (cg-RX-API-DMAC7.html) 2022-11-21
JP7616995B2 JP7616995B2 (ja) 2025-01-17

Family

ID=70852200

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530800A Active JP7616995B2 (ja) 2018-11-28 2019-11-26 神経変性疾患のための遺伝子治療
JP2024128634A Withdrawn JP2024177670A (ja) 2018-11-28 2024-08-05 神経変性疾患のための遺伝子治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024128634A Withdrawn JP2024177670A (ja) 2018-11-28 2024-08-05 神経変性疾患のための遺伝子治療

Country Status (11)

Country Link
US (1) US20220010001A1 (cg-RX-API-DMAC7.html)
EP (1) EP3887396A4 (cg-RX-API-DMAC7.html)
JP (2) JP7616995B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210096168A (cg-RX-API-DMAC7.html)
CN (1) CN113557243A (cg-RX-API-DMAC7.html)
AU (1) AU2019388975A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021010234A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121211A1 (cg-RX-API-DMAC7.html)
IL (1) IL283496B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006253A (cg-RX-API-DMAC7.html)
WO (1) WO2020112802A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3692158A4 (en) 2017-10-03 2021-08-04 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISEASES
MX2020004005A (es) 2017-10-03 2020-10-05 Prevail Therapeutics Inc Terapias genicas para los trastornos lisosomales.
JP2023500793A (ja) * 2019-10-16 2023-01-11 コーネル・ユニバーシティー アルツハイマー病に対する遺伝子治療方法
KR20220107243A (ko) 2019-11-25 2022-08-02 코넬 유니버시티 Apoe 유전자 요법
AU2021364596A1 (en) * 2020-10-22 2023-06-08 Duke University Compositions and methods relating to alzheimer's disease
KR20230112672A (ko) * 2020-11-25 2023-07-27 프리베일 테라퓨틱스, 인크. 신경변성 질환을 위한 유전자 요법
WO2023078883A1 (en) * 2021-11-03 2023-05-11 F. Hoffmann-La Roche Ag Oligonucleotides for modulating apolipoprotein e4 expression
AR131035A1 (es) * 2022-11-11 2025-02-12 Lilly Co Eli Ácidos nucleicos sintéticos que incluyen constructos promotores dirigidos a astrocitos y métodos de uso de los mismos
CN119220609B (zh) * 2024-09-27 2025-09-12 科辉智药(深圳)新药研究中心有限公司 一种共表达TRIM11和ApoE2的核酸序列构建体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2142300C (en) * 1992-10-13 2005-08-23 Allen D. Roses Methods for detecting alzheimer's disease
ATE387459T1 (de) * 2000-04-06 2008-03-15 Kos Pharma Inc Verbindungen und methoden zur senkung des cholesterinspiegels ohne induktion von hypertriglyceridämie
US20050019927A1 (en) * 2003-07-13 2005-01-27 Markus Hildinger DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
EP1991252A2 (en) * 2006-02-21 2008-11-19 Oklahoma Medical Research Foundation Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
US20150183850A1 (en) * 2012-05-18 2015-07-02 University Of Iowa Research Foundation Methods and compositions for treating amyloid deposits
WO2013181618A2 (en) * 2012-05-31 2013-12-05 The Trustees Of Columbia University In The City Of New York Methods to treat alzheimer's disease using apoe inhibitors
WO2014028461A2 (en) * 2012-08-13 2014-02-20 The Rockefeller University Treatment and diagnosis of melanoma
ES2874704T3 (es) * 2013-11-20 2021-11-05 Univ Iowa Res Found Procedimiento para monitorizar la eficacia de un tratamiento de la enfermedad de Alzheimer con una isoforma de ApoE
WO2015153760A2 (en) * 2014-04-01 2015-10-08 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a nervous system disorder
EP3191578B1 (en) * 2014-09-12 2020-11-04 Whitehead Institute for Biomedical Research Cells expressing apolipoprotein e and uses thereof
WO2018045347A1 (en) * 2016-09-02 2018-03-08 Spark Therapeutics, Inc. Methods and vectors for treating cns disorders
BR112019023303A2 (pt) * 2017-05-11 2020-06-16 The Trustees Of The University Of Pennsylvania Terapia de gene para lipofuscinoses ceroides neuronais
JP2023500793A (ja) * 2019-10-16 2023-01-11 コーネル・ユニバーシティー アルツハイマー病に対する遺伝子治療方法

Similar Documents

Publication Publication Date Title
US20220331409A1 (en) Factor ix gene therapy
CA3121211A1 (en) Gene therapies for neurodegenerative disease
JP2022531861A5 (cg-RX-API-DMAC7.html)
JP2022060228A5 (cg-RX-API-DMAC7.html)
JP2020537544A5 (cg-RX-API-DMAC7.html)
JP2023503637A5 (cg-RX-API-DMAC7.html)
JP2020537543A5 (cg-RX-API-DMAC7.html)
JP2022549380A5 (cg-RX-API-DMAC7.html)
TW202005978A (zh) 新穎肝靶向腺相關病毒載體
JP2021500049A5 (cg-RX-API-DMAC7.html)
JP2020537542A5 (cg-RX-API-DMAC7.html)
JP2023537625A5 (cg-RX-API-DMAC7.html)
IL278213B1 (en) A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
JP2022530824A5 (cg-RX-API-DMAC7.html)
JP2023537980A5 (cg-RX-API-DMAC7.html)
CA2972038C (en) Adeno-associated virus vectors encoding modified g6pc and uses thereof
US20240318199A1 (en) Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegenerative diseases or disorders
WO2023060269A4 (en) Recombinant adeno-associated viruses for targeted delivery
JP2022530833A5 (cg-RX-API-DMAC7.html)
JP2021507687A5 (cg-RX-API-DMAC7.html)
IL262852B1 (en) Treatment of complement-mediated disorders
WO2021216975A1 (en) Aav native-neuro platform and use for neuronal disease gene therapy
JP2022530095A5 (cg-RX-API-DMAC7.html)
FI3953377T3 (fi) Geeniterapioita lysosomaalisiin sairauksiin
IL300294A (en) Gene therapy using nucleic acid constructs containing methyl CPG-binding protein 2 (MECP2) promoter sequences